NCT03688152 - A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

September 1, 2020

Study Completion Date

September 1, 2020

Conditions

Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma

Interventions

DRUG

INCB053914

"Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."

DRUG

INCB050465

"Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."

Trial Locations (3)

11042

Clinical Research Alliance, Lake Success

85719

University of Arizona Cancer Center, Tucson

90404

UCLA Healthcare Hematology-Oncology, Santa Monica